.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

FDA advisory group likes Macugen but delays formal vote for now

September 15, 2004

New York-Members of the FDA's advisory committee reviewing pegaptanib sodium injection (Macugen) for the treatment of neovascular age-related macular degeneration say they are "impressed" with the drug but declined to take a formal vote.